share_log

BioAffinity Technologies (NASDAQ:BIAFW) Shares Down 3%

Defense World ·  Feb 25, 2023 03:02

bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating)'s share price traded down 3% during mid-day trading on Friday . The company traded as low as $0.33 and last traded at $0.33. 101 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 5,555 shares. The stock had previously closed at $0.34.

bioAffinity Technologies Trading Down 3.0 %

The business's 50 day simple moving average is $0.41.

Get bioAffinity Technologies alerts:

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Armistice Capital LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 204,082 shares of the company's stock, valued at approximately $72,000.

About bioAffinity Technologies

(Get Rating)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.

Further Reading

  • Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
  • Carvana Skidding On Revenue Decrease, Heavy Debt Burden
  • What Are Consumer Staples Stocks?
  • Is Rocky Brands Dividend A Good Fit For Your Portfolio?
  • Beyond Meat Stock Is Not Beyond Hope
  • Analysts Holding As Pfizer Waits On Two Phase 3 Studies

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment